Small sample clinical observation of bevacizumab combined with TAS-102 (Suyuan) and irinotecan in the second-line treatment of RAS wild-type metastatic colorectal cancer

ABSTRACT: Interventions: case group:bevacizumab combined with TAS-102 (Suyuan) and irinotecan Primary outcome(s): Progression-free survival Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2741301 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR